Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST) ― A Prospective Multicenter Study ―
VTE recurrence/worsening occurred in only a small percentage of Japanese cancer-VTE patients treated with rivaroxaban.
Authors
- Nao Muraoka (ORCID: https://orcid.org/0009-0007-3564-039X)
- Masashi Tanaka (ORCID: https://orcid.org/0000-0003-0719-8972)
- Kosei Hasegawa (ORCID: https://orcid.org/0000-0002-1751-6527)
- Rikizo Matsumoto
- Norihiro Kondo
- Hiraku Kumamaru (ORCID: https://orcid.org/0000-0002-9759-6191)
- Yoshito Ogihara (ORCID: https://orcid.org/0000-0002-6659-4660)
- Tetsuro Miyata (ORCID: https://orcid.org/0000-0002-2893-9744)
- Nobutaka Ikeda (ORCID: https://orcid.org/0000-0002-1615-3736)
- Michinari Kono (ORCID: https://orcid.org/0000-0002-9689-0970)
- Yuichi Tamura (ORCID: https://orcid.org/0000-0002-4437-8019)
- Hiroaki Miyata (ORCID: https://orcid.org/0000-0001-8800-6201)
- Masaaki Shoji
- Kunihiro Shigematsu
- Fumie Tsukada
Institutions
- Toho University (JP)
- Mie University (JP)
- Keio University (JP)
- University Medical Center (US)
- Shizuoka Cancer Center (JP)
- National Cancer Center (US)
- Toho University Ohashi Medical Center (JP)
- Tokushima University Hospital (JP)
- Japan Organization of Occupational Health and Safety (JP)
- Mita Hospital (JP)
- Nihon University Itabashi Hospital (JP)
- Hirosaki University Hospital (JP)
- International University of Health and Welfare (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Circulation Journal
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1253/circj.cj-25-0541
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Intuitive Surgical
- Nipro
- Daiichi-Sankyo
- Novartis Pharma
- Bayer Yakuhin